SAN DIEGO, Sept. 26, 2018 /PRNewswire/ -- Avelas Biosciences, Inc., a clinical stage oncology-focused platform technology company that is developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention, today announced that Ms. Kyri Van Hoose, Head of Finance, will present at the 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018, at 8:35 a.m. EDT (5:35 a.m. PDT) in New York City.
About Avelas Biosciences
Avelas Biosciences is a San Diego-based biotechnology company focused on developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention. The company's lead candidate, AVB-620, has completed a Phase 1b clinical trial assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. A Phase 2 clinical trial for AVB-620 in breast cancer is ongoing. In addition, the company is advancing a therapeutic program, which utilizes the same technology platform. Avelas was founded on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry. For additional information, please visit www.avelasbio.com.
Advertisement
About Avelas Biosciences
Avelas Biosciences is a San Diego-based biotechnology company focused on developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention. The company's lead candidate, AVB-620, has completed a Phase 1b clinical trial assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. A Phase 2 clinical trial for AVB-620 in breast cancer is ongoing. In addition, the company is advancing a therapeutic program, which utilizes the same technology platform. Avelas was founded on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry. For additional information, please visit www.avelasbio.com.
Advertisement
View original content:http://www.prnewswire.com/news-releases/avelas-biosciences-to-present-at-2018-cantor-global-healthcare-conference-300719108.html
SOURCE Avelas Biosciences, Inc.
